Jove
Visualize
Contact Us

Related Experiment Videos

[Cholestatic hepatitis caused by midecamycin]

J M Pérez Moreno1, F J Saldaña González, M Puertas Montenegro

  • 1Sección de Aparato Digestivo, Hospital Universitario de Puerto Real, Cádlz.

Gastroenterologia Y Hepatologia
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Nimesulide toxic hepatitis in pregnancy].

Gastroenterologia y hepatologia·2001
Same author

[Toxic hepatitis caused by aceclofenac].

Revista espanola de enfermedades digestivas·1996
Same author

[Infective endocarditis in heroin addicts in the province of Cádiz. A multicenter study of 150 cases].

Medicina clinica·1992
Same author

[Acquired immunodeficiency syndrome in the province of Cádiz. A study of 269 consecutive patients].

Medicina clinica·1991
Same author

[Rhabdomyolysis and renal insufficiency as complications of acute gastroenteritis caused by salmonella enteritidis].

Anales de medicina interna (Madrid, Spain : 1984)·1991
Same author

[Infective endocarditis in heroin addicts in the province of Cadiz].

Medicina clinica·1989
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Macrolide antibiotics, like erythromycin, can cause liver damage. This case study details a rare instance of cholestatic hepatitis linked to diacetyl midecamycin, resolving after drug cessation.

Area of Science:

  • Pharmacology
  • Hepatology
  • Clinical Medicine

Background:

  • Macrolide antibiotics, including erythromycin and its derivatives, are known for potential hepatotoxicity.
  • Midecamycin, a semi-synthetic macrolide, generally exhibits a favorable safety profile.
  • Isolated reports suggest potential secondary hepatobiliary effects from midecamycin.

Observation:

  • This report details a clinical observation of a patient who developed cholestatic hepatitis.
  • The adverse event is believed to be associated with the administration of diacetyl midecamycin.
  • The patient's condition improved favorably after discontinuing the drug.

Findings:

  • Diacetyl midecamycin administration was linked to a case of cholestatic hepatitis.
  • The observed hepatotoxicity was cholestatic in nature.

Related Experiment Videos

  • Cessation of diacetyl midecamycin led to a positive clinical outcome.

    • Implications:

    • This case highlights a rare but significant adverse effect of diacetyl midecamycin.
    • Clinicians should be aware of the potential for macrolide-induced liver injury, even with generally safe derivatives.
    • Further investigation into the specific mechanisms of midecamycin-related hepatotoxicity may be warranted.